Get the Stockscreener App
1.00
3.85%
-0.04
Pre-market:
1.02
0.02
+2.00%
Werewolf Therapeutics Inc stock is traded at $1.00, with a volume of 604.95K.
It is down -3.85% in the last 24 hours and up +58.25% over the past month.
Werewolf Therapeutics Inc is a biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer and other immune-mediated conditions. It is leveraging the proprietary PREDATOR platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. It has one reportable segment, which focuses on the discovery and development of cancer therapeutics.
See More
Previous Close:
$1.04
Open:
$1.05
24h Volume:
604.95K
Relative Volume:
1.38
Market Cap:
$48.60M
Revenue:
$1.14M
Net Income/Loss:
$-60.82M
P/E Ratio:
-0.7497
EPS:
-1.3338
Net Cash Flow:
$-60.29M
1W Performance:
+20.11%
1M Performance:
+58.25%
6M Performance:
-48.19%
1Y Performance:
+58.73%
1-Day Range:
$0.9674
$1.08
1-Week Range:
$0.8364
$1.14
52-Week Range:
$0.5301
$2.38
Werewolf Therapeutics Inc Stock (HOWL) Company Profile
Name
Werewolf Therapeutics Inc
Sector
Industry
Phone
617-952-0555
Address
200 TALCOTT AVENUE, WATERTOWN
Compare HOWL vs VRTX, REGN, ARGX, ALNY, INSM
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
HOWL
Werewolf Therapeutics Inc
|
1.00 | 48.60M | 1.14M | -60.82M | -60.29M | -1.3338 |
VRTX
Vertex Pharmaceuticals Inc
|
431.86 | 109.85B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
760.27 | 80.38B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
765.43 | 47.60B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
319.52 | 42.63B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
163.03 | 35.19B | 606.42M | -1.28B | -997.58M | -6.403 |
Werewolf Therapeutics Inc Stock (HOWL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-19-25 | Downgrade | Wedbush | Outperform → Neutral |
| Apr-03-24 | Initiated | JMP Securities | Mkt Outperform |
| Aug-24-23 | Initiated | Wedbush | Outperform |
| Jun-06-23 | Resumed | Jefferies | Buy |
| Sep-10-21 | Initiated | BofA Securities | Buy |
| May-25-21 | Initiated | Evercore ISI | Outperform |
| May-25-21 | Initiated | H.C. Wainwright | Buy |
| May-25-21 | Initiated | Jefferies | Buy |
| May-25-21 | Initiated | SVB Leerink | Outperform |
View All
Werewolf Therapeutics Inc Stock (HOWL) Latest News
Werewolf Therapeutics (NASDAQ:HOWL) Raised to “Hold” at Wall Street Zen - Defense World
HOWL Technical Analysis & Stock Price Forecast - Intellectia AI
HOWL Forecast, Price Target & Analyst Ratings | WEREWOLF THERAPEUTICS INC (NASDAQ:HOWL) - ChartMill
Investment Report: Is now the right time to enter Werewolf Therapeutics IncWeekly Trend Recap & Capital Efficient Trading Techniques - baoquankhu1.vn
Werewolf Therapeutics Faces Nasdaq Delisting Risk After Falling Below $1 Minimum Bid Price - TipRanks
HOWL PE Ratio & Valuation, Is HOWL Overvalued - Intellectia AI
HOWL Should I Buy - Intellectia AI
Aug Action: Is now the right time to enter Werewolf Therapeutics Inc2026 Technical Patterns & Accurate Buy Signal Alerts - baoquankhu1.vn
Werewolf Therapeutics (HOWL) price target increased by 20.19% to 6.38 - MSN
Werewolf Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Updates - bitget.com
Werewolf Therapeutics reports Q4 EPS (20c), consensus (35c) - tipranks.com
Werewolf Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - MarketScreener
Werewolf Therapeutics, Inc. (HOWL) Reports Q4 Earnings - AlphaStreet
Werewolf Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Werewolf Therapeutics Reports 2025 Financial Results and Advances Cancer Therapy Clinical Pipeline - geneonline.com
Werewolf Therapeutics (HOWL) faces going‑concern risk while IL‑2 and IL‑12 candidates show early responses - Stock Titan
Werewolf Therapeutics 10-K: Revenue $0M, Net Loss $(60.82)M - TradingView
Earnings Scheduled For March 27, 2026 - Benzinga
HOWL: Strategic review underway with improved financials and continued progress in oncology pipeline - tradingview.com
Werewolf Therapeutics (NASDAQ: HOWL) cuts 2025 loss and launches strategic review - Stock Titan
Aug Drivers: Is Werewolf Therapeutics Inc a speculative investment2026 Technical Patterns & Low Risk High Reward Ideas - baoquankhu1.vn
Biotech 'Lowballed' Landlord On Lease Exit, Suit Says - Law360
Werewolf Therapeutics Inc expected to post a loss of 34 cents a shareEarnings Preview - TradingView
HOWL Stock Price, Quote & Chart | WEREWOLF THERAPEUTICS INC (NASDAQ:HOWL) - ChartMill
Aug Setups: Is Intelligent Bio Solutions Inc part of any major index2026 Trends & Weekly Breakout Watchlists - baoquankhu1.vn
Michael J. Urban Net Worth (2026) - GuruFocus
Werewolf Therapeutics (HOWL) eyes 2026 catalysts following FDA guidance and encouraging INDUKINE results - MSN
RSI Check: Is Werewolf Therapeutics Inc stock trending bullishTrade Exit Report & Growth Oriented Trading Recommendations - baoquankhu1.vn
Analyst Downgrade: Is now the right time to enter Werewolf Therapeutics IncLayoff News & Real-Time Volume Triggers - baoquankhu1.vn
Werewolf Therapeutics (HOWL) finance VP reports stock and option holdings on Form 3 - Stock Titan
Werewolf Therapeutics stock rises over 5% after hours on workforce reduction, including executives - MSN
Werewolf Therapeutics (HOWL) Stock Analysis Report | Financials & Insights - Benzinga Japan
Werewolf Therapeutics (HOWL) price target decreased by 10.86% to 5.30 - MSN
Published on: 2026-03-05 15:55:35 - baoquankhu1.vn
Werewolf Therapeutics Stock Rises Over 5% After Hours On Workforce Reduction, Including Executives - Stocktwits
HOWL Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Werewolf Therapeutics (HOWL) Expected to Announce Quarterly Earnings on Tuesday - Defense World
HOWL Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
Is now the right time to enter Werewolf Therapeutics IncTrade Entry Report & Weekly Watchlist for Consistent Profits - baoquankhu1.vn
Werewolf Therapeutics Inc expected to post a loss of 35 cents a shareEarnings Preview - TradingView
Werewolf Therapeutics announces plan to explore strategic alternatives - MSN
Werewolf Therapeutics explores sale and strategic alternatives - Investing.com India
Werewolf Therapeutics Announces Plan to Explore Strategic Alternatives - The Manila Times
Werewolf Therapeutics Begins Strategic Alternatives Review Process - TipRanks
Werewolf Therapeutics (HOWL) starts review of strategic options with Piper Sandler - Stock Titan
Werewolf Therapeutics explores sale and strategic alternatives By Investing.com - Investing.com South Africa
Werewolf to Explore Strategic Alternatives, Engages Piper Sandler as Exclusive Advisor - tradingview.com
Levels Update: Does Werewolf Therapeutics Inc have strong EBITDA marginsJuly 2025 Spike Watch & Short-Term Trading Opportunity Alerts - baoquankhu1.vn
HOWL Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Why Werewolf Therapeutics Inc. stock could rally in 2025Portfolio Gains Summary & Smart Swing Trading Techniques - mfd.ru
IPO Launch: Does Werewolf Therapeutics Inc have strong EBITDA margins2025 Analyst Calls & Risk Controlled Daily Plans - baoquankhu1.vn
Werewolf Therapeutics Inc Stock (HOWL) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.47%
2.75%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):